ArticleClinical and vaccine immunology : CVI2013
Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.
Article in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Toll-Like Receptor 3 is Associated With the Risk of HCV Infection and HBV-Related Diseases.Medicine · 2016Pooled it
- Toll-like receptor 3 expression and function in childhood idiopathic nephrotic syndrome.Clinical and experimental immunology · 2015Trial
- Analysis of Glaucoma Associated Genes in Response to Inflammation, an Examination of a Public Data Set Derived from Peripheral Blood from Patients with Hepatitis C.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Article
- Ubiquitin-related molecular classification and risk stratification of hepatocellular carcinoma.Molecular therapy oncolytics · 2021Article
- Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.Frontiers in immunology · 2021Review
- Association of TLR3 single nucleotide polymorphisms with susceptibility to HTLV-1 infection in Iranian asymptomatic blood donors.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
- Participation of Endosomes in Toll-Like Receptor 3 Transportation Pathway in Murine Astrocytes.Frontiers in cellular neuroscience · 2020Article
- Classical swine fever virus Shimen infection increases p53 signaling to promote cell cycle arrest in porcine alveolar macrophages.Oncotarget · 2017Article
- Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection.Journal of immunology research · 2017Article
- HCV core protein binds to gC1qR to induce A20 expression and inhibit cytokine production through MAPKs and NF-κB signaling pathways.Oncotarget · 2016Article
- Polymorphisms of the Toll-Like Receptor-3 Gene in Autoimmune Adrenal Failure and Type 1 Diabetes in Polish Patients.Archivum immunologiae et therapiae experimentalis · 2016Article
- Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing.Integrative biology : quantitative biosciences from nano to macro · 2015Article
- Up-regulation of A20/ABIN1 contributes to inefficient M1 macrophage polarization during Hepatitis C virus infection.Virology journal · 2015Article
- Systems immunology reveals markers of susceptibility to West Nile virus infection.Clinical and vaccine immunology : CVI · 2015Article
- CyTOF supports efficient detection of immune cell subsets from small samples.Journal of immunological methods · 2014Article
- The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.Trends in parasitology · 2014Review
- Immune markers associated with host susceptibility to infection with West Nile virus.Viral immunology · 2014Article
- Role of innate immunity in the development of hepatocellular carcinoma.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis C virus (HCV) is the most common chronic blood-borne infection in the United States, with the majority of patients becoming chronically infected and a subset (20%) progressing to cirrhosis and hepatocellular carcinoma. Individual variations in immune responses may help define successful resistance to infection with HCV. We have compared the immune response in primary macrophages from patients who have spontaneously cleared HCV (viral load negative [VL-], n = 37) to that of primary macrophages from HCV genotype 1 chronically infected (VL+) subjects (n = 32) and found that macrophages from VL- subjects have an elevated baseline expression of Toll-like receptor 3 (TLR3). Macrophages from HCV patients were stimulated ex vivo through the TLR3 pathway and assessed using gene expression arrays and pathway analysis. We found elevated TLR3 response genes and pathway activity from VL- subjects. Furthermore, macrophages from VL- subjects showed higher production of beta interferon (IFN-β) and related IFN response genes by quantitative PCR (Q-PCR) and increased phosphorylation of STAT-1 by immunoblotting. Analysis of polymorphisms in TLR3 revealed a significant association of intronic TLR3 polymorphism (rs13126816) with the clearance of HCV and the expression of TLR3. Of note, peripheral blood mononuclear cells (PBMCs) from the same donors showed opposite changes in gene expression, suggesting ongoing inflammatory responses in PBMCs from VL+ HCV patients. Our results suggest that an elevated innate immune response enhances HCV clearance mechanisms and may offer a potential therapeutic approach to increase viral clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.